Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05609578 · ClinicalTrials.gov registry record · Phase 2

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

A Phase 2 study of Metastatic Lung Cancer and Advanced NSCLC, sponsored by Mirati Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
20
Study locations

NCT05609578 is a Phase 2 study of Metastatic Lung Cancer and Advanced NSCLC that is actively recruiting participants, run by Mirati Therapeutics. The registered enrollment target is 90 participants, below the 167-participant average among 10 other Metastatic Lung Cancer trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05609578, a Phase 2 study of Metastatic Lung Cancer and Advanced NSCLC, is actively recruiting participants, sponsored by Mirati Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

Conditions Studied

Metastatic Lung Cancer Advanced NSCLC

Interventions

  • COMBINATION_PRODUCT Pembrolizumab
  • DRUG Adagrasib oral dose of 400 mg twice daily tablets
  • COMBINATION_PRODUCT Chemotherapy: Pemetrexed
  • COMBINATION_PRODUCT Cisplatin/Carboplatin

Study Locations (20)

Colorado

  • Local Institution - 017-872-I - Aurora
  • Local Institution - 017-872-G - Boulder
  • Local Institution - 017-872-D - Colorado Springs
  • Local Institution - 017-872-J - Colorado Springs
  • Local Institution - 017-872-B - Denver
  • Local Institution - 017-872-F - Denver
  • Local Institution - 017-872-A - Lakewood
  • Local Institution - 017-872-C - Littleton
  • USOR - Rocky Mountain Cancer Centers - Lone Tree - Sky Ridge Medical Center - Lone Tree
  • Local Institution - 017-872-E - Pueblo

California

  • Local Institution - Unk047 - Anaheim
  • Local Institution - 017-936C - Fountain Valley
  • MemorialCare - Orange Coast Medical Center - Fountain Valley
  • Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton - Fullerton
  • Local Institution - Unk004 - Loma Linda
  • Local Institution - 017-961 - Los Angeles
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Arizona

  • Local Institution - 017-591 - Glendale
  • Local Institution - 017-821 - Phoenix

Alaska

  • Local Institution - Unk025 - Anchorage

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2022-11-22
Est. Completion 2026-12-01
Phase Phase 2

Sponsor

Mirati Therapeutics

49 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05609578

The ClinicalTrials.gov registry entry for NCT05609578 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 167-participant average among 10 other Metastatic Lung Cancer trials with a reported enrollment target (46% lower). The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT05609578 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Colorado, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT05609578 about?

NCT05609578 is a clinical study titled "Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation". Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

What is the current status of trial NCT05609578?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2022-11-22. Estimated completion is 2026-12-01.

What conditions does trial NCT05609578 study?

This clinical trial studies the following conditions: Metastatic Lung Cancer, Advanced NSCLC.

What interventions are being tested in trial NCT05609578?

The interventions under investigation include: Pembrolizumab (COMBINATION_PRODUCT), Adagrasib oral dose of 400 mg twice daily tablets (DRUG), Chemotherapy: Pemetrexed (COMBINATION_PRODUCT), Cisplatin/Carboplatin (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05609578?

This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05609578 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Lung Cancer

All registered trials for this condition

Advanced NSCLC

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.